Naringenin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration and decreases neointimal hyperplasia in balloon injured rat carotid arteries through suppressing oxidative stress

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 10, 2013, Pages 1549-1555

  Xu, Changwu ^a   Chen, Jing ^a   Zhang, Jing ^a   Hu, Xiaorong ^a   Zhou, Xiaoya ^a   Lu, Zhibing ^a   Jiang, Hong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Angiotensin II; Naringenin; Neointimal hyperplasia; Oxidative stress; Vascular smooth muscle cell

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN II; ANTIOXIDANT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NARINGENIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CAROTID ARTERY INJURY; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PROSTAGLANDIN BLOOD LEVEL; PROTEIN SYNTHESIS; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL PROLIFERATION; CITRUS; CORONARY RESTENOSIS; DINOPROST; FLAVANONES; HYPERPLASIA; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUNICA INTIMA;

EID: 84887085080     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00247     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, on behalf of American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation, 127, e6-e245 (2013).
2. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur. Heart J., 31, 642-648 (2010).
3. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet, 354, 708-715 (1999).
4. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ. Cardiovasc. Interv., 5, 476-490 (2012).
5. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation, 107, 2274-2279 (2003). (Pubitemid 36547225)
6. Ishikawa K, Aoyama Y, Hirayama H. Management of drug-eluting stent restenosis. J. Invasive Cardiol., 24, 178-182 (2012).
7. Costa MA, Simon DI. Molecular basis of restenosis and drugeluting stents. Circulation, 111, 2257-2273 (2005). (Pubitemid 40632443)
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809 (1993). (Pubitemid 23132154)
9. Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J. Vasc. Res., 47, 168-180 (2010).
10. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, Kim JK, Jeoung NH, Lee KU, Park IS, Min BH, Park KG, Lee CH, Aronow BJ, Sata M, Lee IK. Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler. Thromb. Vasc. Biol., 29, 1558-1564 (2009).
11. Wang Z, Zhang X, Chen S, Wang D, Wu J, Liang T, Liu C. Lithium chloride inhibits vascular smooth muscle cell proliferation and migration and alleviates injury-induced neointimal hyperplasia via induction of PGC-1alpha. PLoS ONE, 8, e55471 (2013).
12. Won KJ, Jung SH, Lee CK, Na HR, Lee KP, Lee DY, Park ES, Choi WS, Shim SB, Kim B. DJ-1/park7 protects against neointimal formation via the inhibition of vascular smooth muscle cell growth. Cardiovasc. Res., 97, 553-561 (2013).
13. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Quantitation of flavonoid constituents in citrus fruits. J. Agric. Food Chem., 47, 3565-3571 (1999). (Pubitemid 29449470)
14. Pietta PG. Flavonoids as antioxidants. J. Nat. Prod., 63, 1035-1042 (2000).
15. Mershiba SD, Dassprakash MV, Saraswathy SD. Protective effect of naringenin on hepatic and renal dysfunction and oxidative stress in arsenic intoxicated rats. Mol. Biol. Rep., 40, 3681-3691 (2013).
16. Nhiem NX, Kiem PV, Minh CV, Lee JJ, Ku JH, Myung CS, Kim YH. A potential inhibitor of rat aortic vascular smooth muscle cell proliferation from the pollen of Typha angustata. Arch. Pharm. Res., 33, 1937-1942 (2010).
17. Chen S, Ding Y, Tao W, Zhang W, Liang T, Liu C. Naringenin inhibits TNF-alpha induced VSMC proliferation and migration via induction of HO-1. Food Chem. Toxicol., 50, 3025-3031 (2012).
18. Chen J, Zhang J, Xu L, Xu C, Chen S, Yang J, Jiang H. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor. Atherosclerosis, 224, 332-339 (2012).
19. Li Z, Shi K, Guan L, Cao T, Jiang Q, Yang Y, Xu C. ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett., 584, 2291-2297 (2010).
20. Yang J, Jiang H, Chen SS, Chen J, Li WQ, Xu SK, Wang JC. Lentivirus- mediated RNAi targeting CREB binding protein attenuates neointimal formation and promotes re-endothelialization in balloon injured rat carotid artery. Cell. Physiol. Biochem., 26, 441-448 (2010).
21. Renugadevi J, Prabu SM. Naringenin protects against cadmium-induced oxidative renal dysfunction in rats. Toxicology, 256, 128-134 (2009).
22. Tulis DA. Rat carotid artery balloon injury model. Methods Mol. Med., 139, 1-30 (2007).
23. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J., 18, 1791-1800 (2004). (Pubitemid 39602265)
24. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA, 295, 1681-1687 (2006).
25. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc. Res., 71, 247-258 (2006).
26. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J. Clin. Invest., 93, 788-798 (1994).
27. Kohno M, Ohmori K, Nozaki S, Mizushige K, Yasunari K, Kano H, Minami M, Yoshikawa J. Effects of valsartan on angiotensin IIinduced migration of human coronary artery smooth muscle cells. Hypertens. Res., 23, 677-681 (2000). (Pubitemid 32007632)
28. Dong X, Yu LG, Sun R, Cheng YN, Cao H, Yang KM, Dong YN, Wu Y, Guo XL. Inhibition of PTEN expression and activity by angiotensin II induces proliferation and migration of vascular smooth muscle cells. J. Cell. Biochem., 114, 174-182 (2013).
29. Lee JJ, Yi H, Kim IS, Kim Y, Nhiem NX, Kim YH, Myung CS. (2S)-naringenin from Typha angustata inhibits vascular smooth muscle cell proliferation via a G0/G1 arrest. J. Ethnopharmacol., 139, 873-878 (2012).
30. Yang Y, Xu Y, Xia T, Chen F, Zhang C, Liang W, Lai L, Fang X. A single-molecule study of the inhibition effect of naringenin on transforming growth factor-beta ligand-receptor binding. Chem. Commun. (Camb.), 47, 5440-5442 (2011).
31. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol., 91 (3A), 7A-11A (2003). (Pubitemid 36351457)
32. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid. Redox Signal., 12, 675-682 (2010).
33. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol., 25, 29-38 (2005). (Pubitemid 40054251)
34. Bronas UG, Dengel DR. Influence of vascular oxidative stress and inflammation on the development and progression of atherosclerosis. American Journal of Lifestyle Medicine, 4, 521-534 (2010).
35. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp. Physiol., 90, 449-455 (2005). (Pubitemid 40980144)
36. Wosniak J Jr, Santos CX, Kowaltowski AJ, Laurindo FR. Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid. Redox Signal., 11, 1265-1278 (2009).
37. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, Chandrasekar B. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am. J. Physiol. Heart Circ. Physiol., 303, H282-H296 (2012).
38. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, Kreuzer J. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler. Thromb. Vasc. Biol., 20, 940-948 (2000). (Pubitemid 30207566)
39. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today, 11, 524-533 (2006).
40. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal., 15, 1583-1606 (2011).
41. Jeon SM, Kim HK, Kim HJ, Do GM, Jeong TS, Park YB, Choi MS. Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats. Transl. Res., 149, 15-21 (2007). (Pubitemid 44969644)
42. Luo YL, Zhang CC, Li PB, Nie YC, Wu H, Shen JG, Su WW. Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke. Int. Immunopharmacol., 13, 301-307 (2012).
43. Ebrahimian T, Li MW, Lemarie CA, Simeone SM, Pagano PJ, Gaestel M, Paradis P, Wassmann S, Schiffrin EL. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension, 57, 245-254 (2011).
44. Cayci C, Wahlquist TC, Seckin SI, Ozcan V, Tekinay AB, Martens TP, Oz MC, Ascherman JA. Naringenin inhibits neointimal hyperplasia following arterial reconstruction with interpositional vein graft. Ann. Plast. Surg., 64, 105-113 (2010).